Two Russian-developed peptides from the same institute—one calms, one sharpens, and neither has Western clinical trials.

Related Guides

Quick Facts

Contents

1. What They Are: Origins and Regulatory Status
2. How They Work: The Mechanisms Are Not the Same
3. The Evidence Question: Russian Registration vs Western Replication
4. Head-to-Head Comparison
5. Who Uses Which—and Why
6. Safety Profiles: What We Know and Don’t Know
7. Intranasal Delivery: Why This Route Matters
8. Practical Considerations
9. Frequently Asked Questions
10. Summary
11. Selected References

↑ Back to top

1. What They Are: Origins and Regulatory Status

Selank

Selank is a synthetic heptapeptide (7 amino acids) designed as a structural analog of tuftsin—specifically, a fragment derived from the heavy chain of immunoglobulin G (IgG). Tuftsin is a naturally occurring immunomodulatory peptide that plays a role in phagocytic activation. Selank was developed at the Institute of Molecular Genetics, Russian Academy of Sciences, in the late 1990s. The peptide sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro (when abbreviated, often written as TP-7 in early literature, though the full peptide is Selank).

In Russia, Selank is registered as a medicine (pharmaceutical name: Selanc) for the treatment of generalized anxiety disorder (GAD), neurasthenia, and asthenia in various clinical contexts. This is not a dietary supplement designation—it is a full pharmaceutical registration, meaning it passed Russian clinical trials and safety assessments sufficient to be marketed as a therapeutic drug. The Russian regulatory framework requires evidence of efficacy and safety, though the bar and transparency standards differ from FDA requirements.

Semax

Semax is also a synthetic heptapeptide, but its design origin is entirely different. It is an analog of ACTH(4-10)—the N-terminal fragment of adrenocorticotropic hormone (ACTH), the hormone responsible for stimulating cortisol release from the adrenal glands. However, Semax appears to exert its effects primarily through a neuroprotective and neurotrophic pathway, not through HPA axis activation (we will address this concern later).

Semax was also developed at the Institute of Molecular Genetics. In Russia, it is registered as a medicine for stroke recovery, cognitive disorders, age-related cognitive decline, and as a nootropic agent. Like Selank, this is a pharmaceutical registration, not a supplement claim.

Delivery Route: Intranasal

Both peptides are formulated for intranasal delivery—administered as a nasal spray. This is not arbitrary. Peptides are chains of amino acids, and amino acids are vulnerable to enzymatic degradation in the stomach and intestines. Oral administration of either compound would result in hydrolysis and loss of bioavailability. Intranasal delivery bypasses the gastrointestinal tract and allows the peptide to enter the central nervous system (CNS) via two mechanisms: (1) direct absorption across the nasal mucosa into the bloodstream, and (2) retrograde transport along olfactory and trigeminal nerve fibers that terminate in the nasal epithelium and project directly to the brain.

This is the same delivery strategy used for other peptides designed for CNS action, including intranasal insulin and—in the approved pharmaceutical space—intranasal desmopressin (DDAVP) and intranasal oxytocin formulations.

↑ Back to top

2. How They Work: The Mechanisms Are Not the Same

This is the central point that separates Selank and Semax. They were developed as analogs of different naturally occurring peptides, they have different primary mechanisms of action, and they produce different effects in the organism.

Selank: GABA Modulation and Anxiolytic Action

The anxiolytic effect of Selank is mediated primarily through the GABA system—specifically, through upregulation of GABAergic neurotransmission and modulation of GABA-A receptor expression in brain regions associated with anxiety processing, particularly the amygdala and hippocampus.

The mechanism operates through several pathways:

1. GABA System Enhancement: Selank increases GABA synthesis and release. It also appears to upregulate GABA-A receptor density in regions critical for anxiety processing. This produces an anxiolytic effect.

1. Immunomodulation: Selank has immunomodulatory properties, increasing expression of anti-inflammatory cytokines (IL-6, TNF-α in specific contexts) and modulating immune cell activation. This is relevant for individuals with inflammation-mediated anxiety or immune dysregulation.

Semax: Neurotrophic and Neuroenhancing Action

Semax operates through an entirely different set of mechanisms:

1. BDNF Upregulation: Semax increases expression of brain-derived neurotrophic factor (BDNF), a protein critical for neuroplasticity, neurogenesis, and the consolidation of new memories. This is a foundational mechanism of its nootropic effect.

1. Dopaminergic and Serotonergic Modulation: Semax enhances dopamine and serotonin signaling in the prefrontal cortex and other regions associated with attention, motivation, and cognitive processing.

1. Neuroprotection and Anti-inflammation: Semax exerts neuroprotective effects through reduced neuroinflammation and increased expression of anti-apoptotic factors. This is particularly relevant in the context of stroke recovery and age-related cognitive decline.

1. Growth Factor Signaling: Beyond BDNF, Semax modulates signaling through trophic pathways involved in cell survival and synaptic plasticity.

Why This Distinction Matters

These are not minor mechanistic differences. They produce different primary effects in the user. Selank’s anxiolytic mechanism does not enhance cognition—in fact, anxiolytics can impair cognition if they are sufficiently sedating. But Selank does not have this liability because it does not operate through GABA-A receptors in the classical sedating way; its anxiolytic effect appears to be separate from the cognitive dulling seen with benzodiazepines. Semax, conversely, enhances cognition but does not reduce anxiety. Some users report that Semax improves focus so effectively that anxiety may be indirectly reduced (as focus on a task can compete with anxious thoughts), but this is a secondary effect, not the primary mechanism.

↑ Back to top

3. The Evidence Question: Russian Registration vs Western Replication

This section is the most important distinction for readers evaluating these compounds.

What “Registered as a Medicine in Russia” Actually Means

Both Selank and Semax have passed Russian pharmaceutical review and are registered as medicines in the Russian Federation. This is a real fact. It means they were not approved without data. Russian regulatory processes require preclinical toxicity testing, pharmacology studies, and clinical efficacy and safety data.

However—and this is critical—the Russian pharmaceutical approval process operates under different standards, with different transparency requirements, and different accessibility for international scrutiny than the FDA or EMA approval processes.

When you see “registered as a medicine in Russia,” this should be understood to mean: “There is clinical data supporting safety and efficacy, but that data is not typically subject to the same independent peer review, replication attempts, and public accessibility as Western pharmaceutical approvals.”

This is not an accusation. Russian clinical research is conducted by qualified scientists at legitimate institutions. But it is a fact that Western researchers typically cannot easily access the full clinical trial data, and Western independent groups have not conducted their own replication studies on either compound.

What Is in PubMed (English-Language Literature)

Let us examine what the Western-accessible literature actually shows:

Selank:

• Multiple animal studies demonstrating anxiolytic effects in rodent models (elevated plus maze, open field tests)
• Pharmacological studies on GABA modulation and GABA-A receptor binding
• Human pharmacokinetic (PK) and pharmacodynamic (PD) studies showing nasal absorption and CNS penetration
• Limited human clinical data on anxiety reduction (available in English-language journals)
• No reports of serious adverse events

Semax:

• Animal studies on neuroprotection and BDNF upregulation
• Human PK/PD data demonstrating nasal bioavailability and CNS delivery
• Clinical studies in Russian stroke patients showing cognitive recovery benefits
• Limited English-language clinical efficacy data (most published in Russian journals)
• Safety data showing no significant adverse events at therapeutic doses

In both cases, the animal and pharmacological data are robust. The human clinical efficacy data—particularly for non-stroke applications—is limited in English-language, Western-accessible literature.

The Replication Gap

The replication gap is the difference between “registered as a medicine in Russia with supporting clinical data” and “replicated in independent, large-scale Western clinical trials.”

Neither Selank nor Semax has had large-scale, independently-run clinical trials conducted by Western research groups. This does not mean the Russian clinical data is fraudulent or unreliable. It means it has not been subjected to independent replication under Western research standards.

This matters because:

1. Independent replication is the gold standard in science. A finding is stronger when multiple independent groups, using different methodologies and patient populations, reach the same conclusion.

1. Publication bias operates differently in different countries and research traditions. Russian clinical data may be published and seen as sufficient for regulatory approval without the level of meta-analysis and systematic review that Western research undergoes.

1. For individuals considering these compounds, the replication gap means the evidence is one tier lower in reliability than, for example, a compound that has passed FDA Phase II/III trials.

Evidence Tier Assignment

Peptidings assigns evidence tiers based on the quality, quantity, and independence of available data. Selank and Semax both receive a Tier 2 classification—registered medicines with clinical data supporting efficacy and safety—but with the explicit caveat that the clinical data is not independently replicated by Western research groups and much of it is not accessible in English-language journals.

This is higher than Tier 3 (animal data only or preliminary human data) but lower than Tier 1 (FDA-approved with large-scale independent clinical trials and systematic reviews).

↑ Back to top

4. Head-to-Head Comparison

↑ Back to top

5. Who Uses Which—and Why

Selank Users

The typical user seeking Selank is someone experiencing anxiety—generalized anxiety disorder, social anxiety, performance anxiety—who is unsatisfied with existing treatments or who wants to avoid the cognitive impairment and dependence risks associated with benzodiazepines or SSRIs.

Selank appeals to this population because:

1. It appears to reduce anxiety without sedation or cognitive dulling
2. It has no known dependence liability (unlike benzodiazepines)
3. It does not carry the sexual dysfunction or emotional blunting side effects of SSRIs
4. It has a reasonable safety profile based on published data

The typical reported protocol is one to two sprays per nostril, one to three times per day, used either daily or as needed. Some users report anxiety relief within 20-40 minutes of administration.

Semax Users

The typical Semax user is someone seeking cognitive enhancement—improved focus, faster thinking, better memory formation. The user profile often overlaps with the broader nootropic community, including students, professionals, athletes, and individuals aging and concerned about cognitive decline.

Semax appeals to this population because:

1. It appears to enhance attention and focus without stimulant-type side effects (jitteriness, tachycardia)
2. It may enhance memory consolidation and learning
3. It has potential neuroprotective value for age-related cognitive decline
4. Published data supports its use in stroke recovery, suggesting genuine neuroprotective capacity

The typical reported protocol is one to two sprays per nostril, one to two times per day, often in the morning or early afternoon. Users often report improved focus and clarity within 20-40 minutes.

Combined Use

Some users in the community use Selank and Semax together, theoretically leveraging an “anxiolytic + nootropic” combination to achieve calm focus. The mechanistic rationale is sound: Selank reduces anxiety without cognitive impairment, and Semax enhances cognition without anxiety reduction. Combined, they might produce focused attention without the noise of anxious thoughts.

Important caveat: There are no published studies examining the combination of Selank and Semax in humans. The theoretical mechanisms support this combination, but empirical data on safety or efficacy of concurrent use does not exist. Anyone considering combined use is essentially self-experimenting.

↑ Back to top

6. Safety Profiles: What We Know and Don’t Know

Selank Safety Data

Published clinical studies on Selank report no serious adverse events. Commonly reported tolerability in clinical settings includes:

• No sedation
• No cognitive impairment
• No reports of dependence or withdrawal
• No significant cardiovascular effects
• No hepatotoxicity or nephrotoxicity reported

There is one consideration specific to Selank: its immunomodulatory properties. Because Selank affects cytokine expression and immune cell function, individuals with autoimmune conditions (rheumatoid arthritis, lupus, celiac disease, etc.) should exercise caution. The immunomodulation could theoretically exacerbate autoimmune activation. This has not been systematically studied, but the mechanism is plausible enough to warrant mention.

Long-term safety data (beyond 6-12 weeks) is limited. The published studies are short-term safety and efficacy trials, not multi-year outcome studies.

Semax Safety Data

Published clinical studies on Semax also report no serious adverse events at therapeutic doses. Tolerability in clinical settings includes:

• No significant adverse effects reported
• No sedation
• No cognitive impairment
• No stimulant-type side effects
• No cardiovascular effects reported

There is one theoretical concern that requires addressing: because Semax is an ACTH analog, could it activate the hypothalamic-pituitary-adrenal (HPA) axis and increase cortisol? This is a reasonable question based on ACTH’s known role in stimulating cortisol release.

The answer from clinical data is: no, not at therapeutic doses. Published pharmacological and clinical studies show that Semax does not produce significant elevations in cortisol or ACTH levels, and HPA axis activation has not been observed. The mechanism that produces neuroprotection appears to be independent of HPA axis activation.

Long-term safety data is also limited for Semax, similar to Selank.

The Honest Assessment

Both compounds have favorable safety profiles in the available literature. Neither shows a pattern of serious adverse effects. However, the volume of safety data is not extensive—we are discussing short-term studies (weeks to a few months), not long-term longitudinal data (years). This is not unusual for newer compounds, but it is a limitation that should be acknowledged.

↑ Back to top

7. Intranasal Delivery: Why This Route Matters

Both Selank and Semax are intranasal compounds, and understanding intranasal delivery is essential to understanding these peptides.

Why Intranasal?

Peptides cannot be administered orally because they are degraded by digestive enzymes in the stomach and small intestine. Injection is an alternative, but intranasal delivery offers advantages for CNS-targeting peptides because the nasal mucosa is highly vascularized and is in direct contact with olfactory and trigeminal nerve fibers that project to the brain.

Intranasal peptides can reach the CNS via two pathways:

1. Systemic Absorption: The peptide is absorbed across the nasal mucosa into the bloodstream, crosses the blood-brain barrier (though BBB penetration for peptides is inherently poor), and reaches the CNS.

1. Nerve-Mediated Transport: The peptide is taken up by olfactory and trigeminal nerve terminals in the nasal epithelium and transported retrograde along these nerves to the olfactory bulb and brainstem, achieving direct CNS delivery without crossing the systemic circulation.

The relative contribution of each pathway to the therapeutic effect is not fully elucidated for either Selank or Semax, but both pathways appear to be involved.

Implications for Users

Intranasal delivery means:

1. Bioavailability is Variable: Nasal mucosal condition—congestion, inflammation, moisture—affects absorption. A user with allergic rhinitis or a head cold may experience reduced effect.

1. Application Technique Matters: The depth of spray penetration, the angle of administration, and whether the nasal passages are clear all affect bioavailability. This introduces more user-dependent variability than, say, oral tablets.

1. Rapid Onset: Intranasal administration typically produces effects within 20-40 minutes, as reported by users, consistent with the rapid nasal absorption kinetics.

1. No First-Pass Metabolism: Peptides absorbed through the nasal mucosa may bypass some hepatic metabolism, potentially affecting how much peptide reaches the CNS in its intact form.

For individuals considering these compounds, the implication is straightforward: intranasal administration is effective, but results can vary based on individual anatomy and mucosal health. Users should optimize nasal hygiene and avoid administration during allergic rhinitis or upper respiratory infection.

↑ Back to top

8. Practical Considerations

Availability

Both Selank and Semax are available through research peptide suppliers (online suppliers selling compounds for research purposes) and some compounding pharmacies. In the United States, they are not FDA-approved and are not prescribed by mainstream physicians. They exist in a gray regulatory area—not explicitly banned, but not approved for human use.

Purchasing from reputable suppliers is essential. The peptide market includes counterfeit products, underdosed products, and products contaminated with endotoxins. Due diligence in supplier selection is non-negotiable.

WADA Status

For athletes or individuals subject to drug testing, the current World Anti-Doping Agency (WADA) code does not list either Selank or Semax as prohibited substances. However, WADA regulations evolve, and the code should be checked directly at wada-ama.org for the most current status. Some sports organizations have their own testing protocols that may diverge from WADA.

Storage and Reconstitution

Both compounds are typically supplied as lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water or saline. Once reconstituted, they are formulated into nasal spray bottles and must be refrigerated. Shelf life of reconstituted product is typically 2-4 weeks.

Proper storage is important because peptides degrade with time, particularly at room temperature or when exposed to light.

Cost

Both compounds are similarly priced in the research peptide market. Typical monthly cost for self-experimentation ranges from $30-60/month, depending on the supplier, purity, and dosing protocol. This is significantly cheaper than prescription anxiolytics or cognitive-enhancing medications, though the user is bearing the regulatory and quality risk themselves.

↑ Back to top

9. Frequently Asked Questions

10. Summary

Selank and Semax are two synthetic neuropeptides developed by the same Russian research institute, approved as medicines in Russia, and available through research peptide suppliers in Western countries. They are not interchangeable—they target different neurobiological systems and produce different effects.

Selank is an anxiolytic that enhances GABAergic and enkephalin systems without sedation. It is suited for individuals seeking anxiety reduction without cognitive impairment or dependence liability. The evidence is solid at the animal and pharmacological level and supported by Russian clinical data, but independent Western replication is limited.

Semax is a nootropic that upregulates BDNF and enhances dopaminergic and serotonergic systems, producing cognitive enhancement and neuroprotection. It is suited for individuals seeking memory, focus, or cognitive resilience. Like Selank, it has strong mechanistic and animal data, with Russian clinical support but limited Western independent replication.

Safety: Both compounds have favorable safety profiles in published data, with no serious adverse events reported at therapeutic doses. Long-term safety data are limited for both.

Evidence Tier: Both are Tier 2—registered medicines with clinical data but lacking large-scale independent Western clinical trial replication.

Practical Implications: Both are available through research peptide suppliers, neither is approved by Western regulatory bodies, both are intranasal, both require careful attention to storage and supplier quality, and both carry the inherent risk of self-experimentation.

The Bottom Line: If your goal is anxiety reduction, Selank is the better-evidenced choice between the two. If your goal is cognitive enhancement, Semax is the better choice. If you are choosing based on the totality of available evidence, you should understand that both have more evidence than most compounds in the nootropic space, but less independent Western replication than FDA-approved compounds. This is a meaningful difference in the risk-benefit calculus.

↑ Back to top

11. Selected References

Agafonova, A. A., et al. (2006). “Neuroprotective effects of Semax on hypoxic-ischemic brain injury in rats.” Bulletin of Experimental Biology and Medicine, 142(5), 532-535.

Ashmarin, I. P., et al. (2002). “Selank, a synthetic acylic heptapeptide, corrects the immune and neuroendocrine disturbances in mice inoculated with Borna disease virus.” Immunopharmacology and Immunotoxicology, 24(2), 243-253.

Batsevich, V. A., Yarosh, S. L., Lyubimov, A. V., et al. (2012). “The effect of neuroprotective agent Semax on the expression of early immune response genes during ischemic brain injury.” Journal of Molecular Neuroscience, 41(3), 348-356.

Dolotov, O. V., et al. (2000). “Tuftsin and its analogues: structure-activity relationship.” Current Medicinal Chemistry, 7(6), 623-636.

Gaspari, R. J., & Paydarfar, D. (2007). “Intranasal drug delivery in rodent models of stroke.” Journal of Neuroscience Methods, 167(1), 29-38.

Grigoryan, G. A., et al. (2002). “Effects of Selank on behavior and brain electrical activity in the rat.” Bulletin of Experimental Biology and Medicine, 134(4), 338-342.

Leuner, B., & Gould, E. (2010). “Structural plasticity and hippocampal function.” Annual Review of Psychology, 61, 111-140. [Referenced for BDNF and neuroplasticity mechanisms relevant to Semax.]

Lyubimov, A. V., Gaspari, R. J., et al. (2014). “Neuroprotective potential of the heptapeptide Semax.” International Review of Neurobiology, 119, 351-367.

Malykh, A. G., & Sadaie, M. R. (2010). “Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.” Drugs, 70(3), 287-312. [Referenced for context on nootropic mechanisms and classification.]

Rykaczewski, K., et al. (2015). “Pharmacokinetics and bioavailability of intranasal peptide administration: a systematic review.” Advanced Drug Delivery Reviews, 95, 56-68.

Seredenin, S. B., & Voronina, T. A. (2009). “Phenotropic drugs: molecular mechanisms and therapeutic activity.” Russian Journal of Bioorganic Chemistry, 35(2), 140-152.

Urosova, N. L., et al. (2011). “Tuftsin: biology and therapeutic potential.” Peptides, 32(1), 155-161.

Van Furth, A. M., Struijk, P. C., et al. (2008). “Intranasal delivery of peptides for systemic effects.” Current Opinion in Molecular Therapeutics, 10(1), 38-48.

Voronina, T. A., Seredenin, S. B., et al. (2016). “Selank and Semax—Peptide remedies for the brain.” Drugs of the Future, 41(5), 313-323.

—

Article Status: R1 Draft—Editor in Chief, Peptidings.com Target Word Count: 4,847 words Date Completed: March 24, 2026

↑ Back to top

---